BridgeMD
Tests treatment safety and results for Chronic Spontaneous Urticaria (CSU)
Official title Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
ClinicalTrials.gov ID: NCT07378527
What this study is testing
What is ICP-332 Tablets?
ICP-332 Tablets is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for chronic spontaneous urticaria (csu).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- 1\. Men and women aged 18 to 75 years.
- 2\. Diagnosis of CSU inadequately controlled by second generation H1-antihistamines.
- 3\. CSU duration for ≥ 6 months prior to randomization.
- 4\. Before initiating any screening or study-specific procedures, the subject must voluntarily sign the informed consent form.
You likely can't join if
- 1\. Having the other medical conditions related to CSU or other skin diseases/conditions.
- 2\. Potential medical conditions or issues.
- 3\. Pregnant female people or lactating female people.
- 4\. The investigator determines that the subject is unsuitable for participating in this study for any reason.
The study team makes the final eligibility decision.
Where it's taking place
- Bengbu, Anhui, China
- Wuhu, Anhui, China
- Beijing, Beijing Municipality, China
- Chongqing, Chongqing Municipality, China
- Fuzhou, Fujian, China
- Guangzhou, Guangdong, China
- Shijiazhuang, Hebei, China
- Luoyang, Henan, China
- Zhengzhou, Henan, China
- Jingzhou, Hubei, China
- Shiyan, Hubei, China
- Changsha, Hunan, China
- Suzhou, Jiangsu, China
- Wuxi, Jiangsu, China
- Zhenjiang, Jiangsu, China
- Changchun, Jilin, China
- Shenyang, Liaoning, China
- Xi'an, Shaanxi, China
- Jinan, Shandong, China
- Shanghai, Shanghai Municipality, China
+ 5 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bengbu, Anhui, China; Wuhu, Anhui, China; Beijing, Beijing Municipality, China; Chongqing, Chongqing Municipality, China; Fuzhou, Fujian, China; Guangzhou, Guangdong, China and 19 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.